Literature DB >> 15734219

Spectra of antinuclear antibodies in patients with squamous cell carcinoma of the lung and of the head and neck.

Félix Fernández Madrid1, Robert L Karvonen, John Ensley, Michael Kraut, José L Granda, Huda Alansari, Naimei Tang, John E Tomkiel.   

Abstract

Squamous cell carcinoma of the head and neck (HNSCC) and of the lung (LSCC) share some important risk factors, but differ substantially in terms of prognosis and treatment. A pulmonary nodule developing in patients with surgically cured HNSCC may pose a diagnostic dilemma. Markers able to distinguish these two common malignancies would be of major clinical importance. In this work we compared the spectrum of antinuclear antibodies (ANA) from 22 patients with SCCL to that of 40 patients with HNSCC. Patient sera were used to probe immunoblots of nuclear extracts from all four major lung cancer cell types, normal lung fibroblasts, cells cultured from a HNSCC, and keratinocytes cultured from the field cancerization. The ability to classify retrospectively LSCC from HNSCC based on serum ANA reactivities was determined by recursive partitioning analyses. We found that while both malignancies share reactivities to a small group of nuclear antigens, other reactivities are directed against proteins uniquely or preferentially expressed in either SCCL or in SCCHN cells. Our work shows that autoimmunity is a prominent feature of squamous cell carcinoma and suggests that molecular characterization of nuclear antigens recognized by ANAs may lead to the discovery of markers valuable to distinguish LSCC from HNSCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15734219      PMCID: PMC5604226          DOI: 10.1016/j.cdp.2004.10.002

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  39 in total

1.  Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking.

Authors:  Suleeporn Sangrajrang; Adisak Sornprom; Gun Chernrungroj; Thierry Soussi
Journal:  Lung Cancer       Date:  2003-03       Impact factor: 5.705

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 3.  Molecular epidemiology of lung cancer.

Authors:  P G Shields
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

4.  p53 mutations in head and neck cancer: new data and evaluation of mutational spectra.

Authors:  A F Olshan; M C Weissler; H Pei; K Conway
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-07       Impact factor: 4.254

5.  Smoking, type of alcoholic beverage and squamous-cell oesophageal cancer in northern Italy.

Authors:  P Zambon; R Talamini; C La Vecchia; L Dal Maso; E Negri; S Tognazzo; L Simonato; S Franceschi
Journal:  Int J Cancer       Date:  2000-04-01       Impact factor: 7.396

Review 6.  Epigenetic tumor markers in plasma and serum: biology and applications to molecular diagnosis and disease monitoring.

Authors:  I H Wong; Y M Lo; P J Johnson
Journal:  Ann N Y Acad Sci       Date:  2001-09       Impact factor: 5.691

7.  The incidence of p53 mutations increases with progression of head and neck cancer.

Authors:  J O Boyle; J Hakim; W Koch; P van der Riet; R H Hruban; R A Roa; R Correo; Y J Eby; J M Ruppert; D Sidransky
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

8.  Autoantibodies to Annexin XI-A and Other Autoantigens in the Diagnosis of Breast Cancer.

Authors:  Félix Fernández-Madrid; Naimei Tang; Huda Alansari; José L Granda; Larry Tait; Kathryn C Amirikia; Mihail Moroianu; Xiaoju Wang; Robert L Karvonen
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

9.  Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma.

Authors:  P P Leong; B Rezai; W M Koch; A Reed; D Eisele; D J Lee; D Sidransky; J Jen; W H Westra
Journal:  J Natl Cancer Inst       Date:  1998-07-01       Impact factor: 13.506

Review 10.  Screening for lung cancer. A critique of the Mayo Lung Project.

Authors:  R S Fontana; D R Sanderson; L B Woolner; W F Taylor; W E Miller; J R Muhm; P E Bernatz; W S Payne; P C Pairolero; E J Bergstralh
Journal:  Cancer       Date:  1991-02-15       Impact factor: 6.860

View more
  7 in total

1.  The clinical significance of anti-mitotic spindle apparatus antibody (MSA) and anti-centromere antibody (ACA) detected in patients with small cell lung cancer (SCLC).

Authors:  Liming Tan; Yuhong Zhang; Yongqing Jiang; Hua Li; Juanjuan Chen; Feng Ming; Waimei Wang; Jianlin Yu; Tingting Zeng; Yongjian Tian; Yang Wu
Journal:  Am J Clin Exp Immunol       Date:  2017-02-15

Review 2.  Usage of cancer associated autoantibodies in the detection of disease.

Authors:  Steven P Dudas; Madhumita Chatterjee; Michael A Tainsky
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

3.  Immunoglobulin G from breast cancer patients in stage I stimulates muscarinic acetylcholine receptors in MCF7 cells and induces proliferation. Participation of nitric oxide synthase-derived nitric oxide.

Authors:  María Pía Negroni; Gabriel L Fiszman; María E Azar; Carlos Cresta Morgado; Alejandro J Español; Laura T Pelegrina; Eulalia de la Torre; María Elena Sales
Journal:  J Clin Immunol       Date:  2010-02-16       Impact factor: 8.317

Review 4.  Improved approach to identify cancer-associated autoantigens.

Authors:  Félix Fernández Madrid; Naimei Tang; Huda Alansari; Robert L Karvonen; John E Tomkiel
Journal:  Autoimmun Rev       Date:  2004-12-13       Impact factor: 9.754

5.  Anti-nuclear antibodies in patients with breast cancer.

Authors:  R Nisihara; M C C Machoski; A Neppel; C A Maestri; I Messias-Reason; T L Skare
Journal:  Clin Exp Immunol       Date:  2018-06-14       Impact factor: 4.330

6.  Autoantibodies in breast cancer sera are not epiphenomena and may participate in carcinogenesis.

Authors:  Félix Fernández Madrid; Marie-Claire Maroun; Ofelia A Olivero; Michael Long; Azadeh Stark; Lawrence I Grossman; Walter Binder; Jingsheng Dong; Matthew Burke; S David Nathanson; Richard Zarbo; Dhananjay Chitale; Rocío Zeballos-Chávez; Carol Peebles
Journal:  BMC Cancer       Date:  2015-05-15       Impact factor: 4.430

7.  Detection of brain-directed autoantibodies in the serum of non-small cell lung cancer patients.

Authors:  Manoj Banjara; Chaitali Ghosh; Aaron Dadas; Peter Mazzone; Damir Janigro
Journal:  PLoS One       Date:  2017-07-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.